Although it must be a great part of the PNS trigger, it cannot explain the whole pathophysiology since CDR2 and CDR2L antigens are found widely in ovarian tumours.32,33 The fact that CDR2 is mostly regulated at the post-transcriptional level may explain why we failed to show a differential expression at RNA.34 On the other hand, CDR1, the other antigen recognised by the anti-Yo antibodies, and CDR2L, are upregulated in anti-Yo PCD OT samples (logFC 1.19 and 1.2 respectively, adjusted p < 0.05). Here, CDR1 is linked to ovarian neoplasm.